Swedish-Nature-09-1248x672

iLite T-Cell Activation Bioassays

A biologically relevant and powerful way to assess CD3 induced T-cell activation

Assay-development-504x672

A biologically relevant way to assess CD3 induced T-cell activation

T-Cell Activation Bioassays

Our T-cell Activation Bioassays, based on Svar’s proprietary iLite® technology, are designed to measure the effectiveness of antibodies engaging with CD3 receptors and triggering T-cell activation – a common mechanism of action (MoA) of therapeutic antibodies.

iLite T-Cell Activation Reporter Gene Assays

Our iLite T-cell activation assays utilize a dual-cell system with luciferase readouts, mimicking the natural interaction of the TCR/CD3 complex. This results in a powerful way of measuring the efficacy of antibodies to elicit T cell activation through CD3 interactions.

  • Easier workflow than traditional T-cell activation Assays
  • "Assay-ready" format for rapid and convenient use
  • A secondary reporter gene that acts as an internal control, compensating for differences in cell number and matrix effects
  • Reduced assay variability

Our T-Cell Activation Reporter-Gene Assays

FILTER VIEW
ALL Effector cells Target cells
QUICK SEARCH
BM5025

iLite® CD19 (+) Target

Engineered to express CD19, this cell line is ideal for ADCC and bispecific antibody assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5025 | ADCC | T-Cell Activation | Cell-based reporter gene assay | Luminescence |
BM5026

iLite® CD19 (-) Target

CD19-negative target cell line used as a specificity control in ADCC and T cell engager assays

CELL-BASED
arrow
Cell-based reporter gene bioassay | Target Cells | BM5026 | ADCC | T-Cell Activation | Cell-based reporter gene assay | Luminescence |
BM5005

iLite® CD3 Effector

Optimized for quantifying T cell-mediated cytotoxicity and bispecific antibody function via CD3 engagement

CELL-BASED
arrow
Cell-based reporter gene bioassay | T-Cell Activation Cells | BM5005 | T-Cell Activation | Cell-based reporter gene assay | Luminescence |

Didn't find what you were looking for?

We offer products customized to your needs. Our custom iLite® reporter-gene assays can be adapted to almost any target. We also offer custom ELISA plates and other products. In addition, you can take advantage of our service offerings and let us do the work for you.

iLite News

previous
Introducing the new iLite® C3a Assay Ready Cells

1 DECEMBER 2025

Introducing the new iLite® C3a Assay Ready Cells

Read post
Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Gets the full picture

6 AUGUST 2025

Take advantage of a more comprehensive way of looking at AAV Immunogenicity – With a Partner Who Get...

Read post
Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therapies

10 JULY 2025

Introducing the AAV Complement Activation Assay: A New Standard in Safety Assessment for Gene Therap...

Read post
Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

2 JULY 2025

Advancing Gene Therapy Research with iLite Assay Ready Cells for AAV Neutralizing Antibody Detection

Read post
AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement

30 JUNE 2025

AAV Safety Assay Platform: The Immunogenicity Trifecta - NAb, TAb & Complement

Read post
next

iLite Downloads

previous
Mechanism-linked potency assays drive Gene Therapy success

Editorial article

Mechanism-linked potency assays drive Gene Therapy success

Read post
Addressing the analytical gaps in modern therapeutic development

White Paper Application Story

Addressing the analytical gaps in modern therapeutic development

Read post
Partnering for success in advanced therapeutics

Partnering for success in advanced therapeutics

Read post
Case Study: How iLite® Technology Enhances Immunogenicity Testing

Case Story

Case Study: How iLite® Technology Enhances Immunogenicity Testing

Read post
Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated Gene Therapy

White Paper

Ensuring Quality and Unmatched Adaptability When Assessing Neutralizing Antibodies in AAV-Mediated G...

Read post
next

20+
years of product development

All 3
complement pathways studied individually

<5h
assay time

265+
scientific paper references

Contact our iLite team

Write us a message and a product specialist will get in touch